400 articles
UT-7
UT-7 (UT7, CVCL_2233) is a human megakaryoblastic leukemia cell line established in 1991 from a 64-year-old Japanese man's bone marrow, absolutely dependent on GM-CSF, IL-3, or erythropoietin, with sublines UT-7/Epo, UT-7/GM, and UT-7/TPO.
Vero
Vero is a continuous cell line derived from African green monkey kidney epithelium, established in Japan in 1962 and widely used to produce viral vaccines, including polio and COVID-19 vaccines.
VU-SCC-147
VU-SCC-147 (93-VU-147T, VU147) is an HPV16-positive head and neck squamous cell carcinoma cell line established at VU University Amsterdam from a floor-of-mouth tumor in a 58-year-old male smoker; Cellosaurus CVCL_L895, HRAS and TP53 mutations, lost chromosome Y.
WERI-Rb-1
WERI-Rb-1 (Wills Eye Research Institute-Retinoblastoma-1, CVCL_1792, ATCC HTB-169) is a human retinoblastoma cancer cell line established in 1974 by McFall and Sery from a 1-year-old girl; suspension-growing, RB1-deleted, with Y79 its companion line.
WI-38 VA13 subline 2RA
WI-38 VA13 subline 2RA (VA13-2RA, CVCL_2759, ATCC CCL-75.1) is an SV40-transformed, immortalized derivative of the WI-38 fetal lung fibroblast line, derived in 1964; an ALT-positive, hyperdiploid model of viral transformation.
WiDr
WiDr (WIDR), a human colon adenocarcinoma cancer cell line first described in 1979, later shown to be a derivative of HT-29 and listed by ICLAC (ICLAC-00103) as misidentified; microsatellite-stable, BRAF V600E, distributed as ATCC CCL-218.
WIL2
WIL2 (WI-L2, CVCL_6544) is an EBV-transformed human B lymphoblastoid cell line established in 1968 from the spleen of a 5-year-old male with hereditary spherocytosis; parent of WIL2-NS, WIL2-S, and TK6.
XP12BE
XP12BE (GM05509, CVCL_F119), also called Jay Tim, is a human XP group A skin fibroblast cell line, compound heterozygous for two XPA splice-site mutations, with under 2% of normal UV-induced DNA repair.
Y-79
Y-79 (Y79, CVCL_1893, ATCC HTB-18) is the first established human retinoblastoma cell line, isolated in 1971 from the right-eye tumor of a 2.5-year-old girl, named for the 79th Yale attempt, RB1-mutant and MYCN-amplified.
ZR-75-1
ZR-75-1 (also ZR751, ATCC CRL-1500) is a human ER/PR-positive breast cancer cell line established in 1978 from the ascites of a 63-year-old woman with infiltrating ductal carcinoma, used widely in endocrine-resistance and ER+ breast cancer research.